Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

LordWorld Feb. 4 at 3:10 PM

$IOBT

0 · Reply

LordWorld Feb. 4 at 9:27 AM

$IOBT

0 · Reply

therealcryptocowboy Feb. 4 at 12:06 AM

$IOBT when announcement🤔👀😤

1 · Reply

badprecog Feb. 4 at 12:05 AM

$IOBT I think anything under probably .40 per share a deal is not doable as shareholders will just be like no liquidate it. So I think anything under that is a blind man’s bluff. Drug is worth $500 million min as it sites. Way more if anyone at big pharma has a brain.

1 · Reply

VinnyLaw Feb. 3 at 10:56 PM

$IOBT Adding more here. I expect a favorable sale of the company in excess of $.5 per share.

1 · Reply

justiceforb_85 Feb. 3 at 8:20 PM

$IOBT adding on a hail mary for the company..

0 · Reply

LordWorld Feb. 3 at 4:50 PM

$IOBT I've seen a lot, and I'm always ready for it.🤣

0 · Reply

therealcryptocowboy Feb. 3 at 4:37 PM

$IOBT shorts could get torched here, hoping for ah news. Not seeing it happening before that!

0 · Reply

therealcryptocowboy Feb. 3 at 1:43 PM

$IOBT added more here😤🤷🏻‍♂️🤔

0 · Reply

LordWorld Feb. 3 at 11:45 AM

$IOBT Zacks 🟢BUY - 🎯 -1,62 $ . forecast from January 31, 2026

0 · Reply

IO Biotech Provides Corporate Update

Jan 21, 2026, 5:30 AM EST - 14 days ago

IO Biotech Announces Exploration of Strategic Alternatives

Dec 15, 2025, 4:05 PM EST - 7 weeks ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 2 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 2 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 3 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 3 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 3 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 4 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 4 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 5 months ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 14, 2025, 4:05 PM EDT - 6 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 6 months ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 6 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 6 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 6 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 9 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 9 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 10 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 10 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 11 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 11 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 2 years ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

LordWorld Feb. 4 at 3:10 PM

$IOBT

0 · Reply

LordWorld Feb. 4 at 9:27 AM

$IOBT

0 · Reply

therealcryptocowboy Feb. 4 at 12:06 AM

$IOBT when announcement🤔👀😤

1 · Reply

badprecog Feb. 4 at 12:05 AM

1 · Reply

VinnyLaw Feb. 3 at 10:56 PM

$IOBT Adding more here. I expect a favorable sale of the company in excess of $.5 per share.

1 · Reply

justiceforb_85 Feb. 3 at 8:20 PM

$IOBT adding on a hail mary for the company..

0 · Reply

LordWorld Feb. 3 at 4:50 PM

$IOBT I've seen a lot, and I'm always ready for it.🤣

0 · Reply

therealcryptocowboy Feb. 3 at 4:37 PM

$IOBT shorts could get torched here, hoping for ah news. Not seeing it happening before that!

0 · Reply

therealcryptocowboy Feb. 3 at 1:43 PM

$IOBT added more here😤🤷🏻‍♂️🤔

0 · Reply

LordWorld Feb. 3 at 11:45 AM

$IOBT Zacks 🟢BUY - 🎯 -1,62 $ . forecast from January 31, 2026

0 · Reply

Nvidioso Feb. 3 at 11:37 AM

$IOBT Today can be a very good day!! Waiting for the announcement...

0 · Reply

justiceforb_85 Feb. 3 at 2:37 AM

$IOBT wondering if there is any hope for this? Science is good but the trial was under-powered. $MRNA with a similar molecule but not in P3.

0 · Reply

LordWorld Feb. 2 at 7:53 PM

$IOBT Let's have some fun

0 · Reply

LordWorld Feb. 2 at 5:01 PM

$IOBT IOBT 🟢Closed negotiations! Biopharma Mogul Summit Organized by: Piper Sandler Investment Bank Where: Park City, Utah (USA) When: February 1–3, 2026 (including today, February 2) Purpose: This is a closed investment event for senior executives of biopharmaceutical and biotechnology companies, investors, and analysts. The goal is informal, private meetings (one-on-one) to discuss investments, partnerships, and potential M&A transactions. ⚠️Now it's clear why they issued two press releases on January 30th, rushed to sign a contract with Raymond James, and announced the dismissal of top manager Kassim Ahmad and the layoff of all staff. The team that worked on T-Win remained and continues to work. In other words, they "cleaned" the company of unnecessary ballast and are ready for sale.

4 · Reply

Sanaci Feb. 2 at 12:38 PM

Nothing substantial: $OSTX keeps going down the $IOBT way

1 · Reply

LordWorld Feb. 2 at 6:11 AM

$IOBT The remaining employees and subordinates are unnecessary waste. That's why, on January 30, 2026, IOBT's press release, following the announcement of Raymond James' hiring, issued a separate statement about Kassim Ahmed's layoffs, with compensation payments. Raymond James is cleaning up and "packaging IOBT" for sale. It seems to me that there's already a buyer, and not just one. One who has set the conditions for IOBT to get rid of all unnecessary stuff. Kassim Ahmed also owns IOBT shares; he bought them with his own money (not a bonus from IOBT), and he hasn't sold a single one yet!

1 · Reply

LordWorld Feb. 1 at 9:08 AM

$IOBT Have you ever wondered why they didn't fire everyone? 🤣 The answer is, whoever acquires it needs the team that worked on T win!!!

1 · Reply

badprecog Jan. 30 at 8:19 PM

$IOBT The more I think about it, the more I think Regeneron could be a buyer. They have a dual action checkpoint inhibitor, but if you had IO Biotech's drug and run it as a 4-pronged therapy. You know you are going to blow out in pdl1- which will be 30-40% of the trial. This drug really is a trail insurance policy for someone. Avg Oncology Drug is $2.6 billion with all the failures to get to approval. One that could put your checkpoint inhibitor in a dominant position... If Raymond James can do a good job here things could end up between crappy and ok for investors. ;)

1 · Reply

LordWorld Jan. 30 at 8:05 PM

$IOBT Scary? 🤣 I averaged it out. I bought shares at 0.298. The news about Raymond James is mostly positive because if such a giant took it on, it means 80% of the company will be sold and most likely there's already a buyer. The fact that it fell is due to external sentiment; the entire market is sliding today, and it's Friday. If things were that bad, why wasn't the price 0.05-0.1???Good luck

0 · Reply

badprecog Jan. 30 at 3:57 PM

$IOBT Right now the pitch RJ is giving: "You have a checkpoint inhibitor, I have a drug that will likely give you the pdl1- market in multiple markets. Low toxicity, if you don't want it, that's ok but don't be mad at me when you lose half the market."

0 · Reply

LordWorld Jan. 30 at 3:25 PM

$IOBT Raymond James is a top-tier player in the healthcare sector. They don't take on hopeless cases unless they have something to sell. The fact that they signed on to the deal confirms that the T-win platform has market value and can be sold.

0 · Reply

badprecog Jan. 30 at 2:25 PM

$IOBT Raymond James specializes in selling 100 million to 2 billion dollar distressed bio assets. So it is the right firm for us. Hopefully they get it done.

1 · Reply

Market Cap	20.87M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	1,919,100
Avg Vol	11,443,233
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	13%
Beta	0.48
Analysts	Sell
Price Target	$1.62